| Bioactivity | HCVcc-IN-1 is a benzothiazole-2-thiophene S-glycoside derivative with low toxic and antiviral activity[1]. |
| Invitro | HCVcc-IN-1 (compound 8c) (0.1, 1, 10, and 100 μg/mL; 1 h) shows antiviral activities against a variety of viruses such as coxsackievirus B4 (CBV4), hepatitis A virus HM 175 (HAV), hepatitis C genotype 4 (HCVcc), adenovirus type 7 (HAdV7), and herpes simplex virus 1 (HSV-1) with viral reduction rates of 86.7%, 66.7%, 23.3%, 66.7%, and 36.7%, respectively[1].HCVcc-IN-1 (0.57-2.0 μg/mL; 1 h) inhibits various virus with IC50 of 0.57 μg/mL (herpes simplex virus), 0.71 μg/mL (HCVcc genotype virus), and 0.69 μg/mL (coxsackievirus B4), respectively; or with CC50 of 2.0 μg/mL (herpes simplex virus), 1.7 μg/mL (HCVcc genotype virus), and 1.7 μg/mL (coxsackievirus B4), respectively[1].HCVcc-IN-1 (5.16-7.23 μg/mL) inhibits hepatitis C virus NS3/4A and HSV-USP7 protease enzyme with IC50s of 5.16 μg/mL and 7.23 μg/mL[1].HCVcc-IN-1 (0.01 mM; 24 h) has low cytotoxicity against FRHK-4, Hep2, BGM, Vero, and Huh 7.5 cell lines[1]. Cell Cytotoxicity Assay[1] Cell Line: |
| Name | HCVcc-IN-1 |
| Formula | C29H25BrN2O8S3 |
| Molar Mass | 705.62 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Azzam et al. Novel Thiophene Thioglycosides Substituted with the Benzothiazole Moiety: Synthesis, Characterization, Antiviral and Anticancer Evaluations, and NS3/4A and USP7 Enzyme Inhibitions. ACS Omega. 2022 Sep 29;7(40):35656-35667. |